Mar 28 |
Eledon Pharmaceuticals GAAP EPS of -$0.32 beats by $0.07
|
Mar 28 |
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
|
Mar 25 |
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
|
Mar 21 |
World’s first pig-to-human kidney transplant performed in U.S
|
Mar 21 |
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
|
Jan 5 |
Eledon Pharmaceuticals reports recent business milestones
|
Jan 4 |
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
|
Dec 25 |
Will Eledon Pharmaceuticals (NASDAQ:ELDN) Spend Its Cash Wisely?
|
Dec 4 |
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Nov 29 |
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
|